Clinical characteristics and outcomes in Epstein-Barr virus positive diffuse large B-cell lymphoma: A retrospective multicenter study
Turkish Journal of Medical Sciences · 14.10.2025 · 55 (5) · 1113-1121
DOI: 10.55730/1300-0144.6066 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Turkish Journal of Medical Sciences, online erschienen am 14.10.2025. Verfasst von Ebru Kiliç Güneş und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Internal Medicine, University of Health Sciences, Gülhane Training and Research Hospital, Ankara, Turkiye. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Epstein-Barr Virus Infections, Herpesvirus 4, Human. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/aimEpstein-Barr virus-positive (EBV+) diffuse large B-cell lymphoma, not otherwise specified (DLBCL-NOS), represents a rare and aggressive subtype of B-cell lymphoma, officially classified as a distinct entity in the revised 4th edition of the World Health Organization (WHO) 2016 classification. This retrospective study aims to evaluate the prevalence, clinical characteristics, histopathological characteristics, and survival results of patients diagnosed with EBV+ DLBCL-NOS.Materials and methodsOur retrospective study included 92 newly diagnosed DLBCL patients treated at two centers between 2016 and 2024. EBV status was determined using in situ hybridization for EBER, with positivity defined as; ≥50% nuclear staining in tumor cells. ResultsAmong 92 patients, 81 (88.1%) were EBV-negative, and 11 (11.9%) were EBV-positive. The median age was 63 years. EBV-positive patients had significantly more advanced-stage disease (100% vs. 71.6%, p=0.049), higher rates of splenic involvement (72.7% vs. 38.3%, p=0.048), elevated LDH levels (median 773 U/L vs. 326 U/L, p=0.043), and a greater proportion with high-risk IPI scores (IPI≥4: 63.6% vs. 27.2%, p=0.032). No differences were observed in age, gender, bulky disease, extranodal involvement, or molecular subtype. Median PFS was 12 months in the EBV-positive group, while it was not reached in the EBV-negative group (p=0.005). EBV positivity was identified as an independent risk factor for inferior PFS (HR: 6.256, 95%CI:2.398–16.324, p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Hematology, Department of Internal Medicine, University of Health Sciences, Gülhane Training and Research Hospital, Ankara, Turkiye.
- Division of Hematology, Department of Internal Medicine, University of Health Sciences, Ankara Etlik City Hospital, Ankara, Turkiye.
ORCID-Profile: Ebru Kiliç Güneş, Hacer Berna Afacan Öztürk, Esra Kiriktir, Asena Dikyar, Bilge Uğur, Ahmet Kürşad Güneş, Meltem Ayli
Zitieren
APA
Kiliç Güneş, E., Afacan Öztürk, H. B., Kiriktir, E., Dikyar, A., Uğur, B., Güneş, A. K., & Ayli, M. (2025). Clinical characteristics and outcomes in Epstein-Barr virus positive diffuse large B-cell lymphoma: A retrospective multicenter study. Turkish Journal of Medical Sciences, 55(5), 1113-1121. https://doi.org/10.55730/1300-0144.6066
Vancouver
Kiliç Güneş E, Afacan Öztürk HB, Kiriktir E, Dikyar A, Uğur B, Güneş AK, et al. Clinical characteristics and outcomes in Epstein-Barr virus positive diffuse large B-cell lymphoma: A retrospective multicenter study. Turkish Journal of Medical Sciences. 2025;55(5):1113-1121. doi:10.55730/1300-0144.6066
BibTeX
@article{KiliGne2025,
author = {Kiliç Güneş, Ebru and Afacan Öztürk, Hacer Berna and Kiriktir, Esra and Dikyar, Asena and Uğur, Bilge and Güneş, Ahmet Kürşad and Ayli, Meltem},
title = {Clinical characteristics and outcomes in Epstein-Barr virus positive diffuse large B-cell lymphoma: A retrospective multicenter study},
journal = {Turkish Journal of Medical Sciences},
year = {2025},
volume = {55},
number = {5},
pages = {1113--1121},
doi = {10.55730/1300-0144.6066}
}
EUVIMED